Table 1 Apaf-1 expression and clinicopathological characteristics of 70 primary melanomas

From: Reduced Apaf-1 expression in human cutaneous melanomas

 

Intensity of Apaf-1 staining

  
 

0

1+

2+

3+

Total

P-valuea

Age

      

 ⩽57

3 (8%)

20 (56%)

9 (25%)

4 (11%)

36

 

 >57

3 (9%)

16 (47%)

12 (35%)

3 (9%)

34

P>0.05

Sex

      

 Male

2 (5%)

18 (47%)

12 (32%)

6 (16%)

38

 

 Female

4 (13%)

18 (56%)

9 (28%)

1 (3%)

32

P>0.05

Tumour thickness (mm)

      

 ⩽0.75

2 (14%)

6 (43%)

4 (29%)

2 (14%)

14

 

 0.76–1.5

4 (10%)

20 (51%)

10 (26%)

5 (13%)

39

 

 1.51–4.0

0 (0%)

7 (64%)

4 (36%)

0 (0%)

11

 

 >4.0

0 (0%)

3 (50%)

3 (50%)

0 (0%)

6

P>0.05b

Ulceration

      

 Absent

6 (10%)

30 (49%)

18 (30%)

7 (11%)

61

 

 Present

0 (0%)

6 (67%)

3 (33%)

0 (0%)

9

P>0.05

Tumour subtype c

      

 SSM

4 (13%)

13 (41%)

12 (38%)

3 (9%)

32

 

 LMM

2 (17%)

5 (42%)

4 (33%)

1 (8%)

12

 

 Other

0 (0%)

18 (69%)

5 (19%)

3 (12%)

26

P>0.05

Site d

      

 Sun-protected

4 (7%)

28 (50%)

18 (32%)

6 (11%)

56

 

 Sun-exposed

2 (14%)

8 (57%)

3 (21%)

1 (7%)

14

P>0.05

  1. aχ2 test for low (0, 1+) vs high Apaf-1 expression (2+, 3+).
  2. bTumours ⩽1.5 mm vs >1.5 mm.
  3. cSSM=superficial spreading melanoma; LMM=lentigo maligna melanoma; Other includes desmoplastic melanoma, acrolentigous melanoma and nodular melanoma.
  4. dSun-protected sites: trunk, arm, leg and feet. Sun-exposed sites: head and neck.
Back to article page